Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Drug

Ascentage Pharma’s APG-2449 Shows Positive Results in ROS1 and ALK Positive NSCLC at ASCO 2024

Fineline Cube Jun 3, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster...

Company Drug

Jacobio Pharma’s KRAS G12C Inhibitor Combo Shows Promising Results in NSCLC at ASCO 2024

Fineline Cube Jun 3, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the...

Policy / Regulatory

NMPA Announces Digitalization of Medical Device Regulatory Documents

Fineline Cube Jun 3, 2024

The National Medical Products Administration (NMPA) has announced a transition to digitalize regulatory documentation for...

Policy / Regulatory

China’s NHSA Launches New Procedures for Drug Catalogue Attribution Identification

Fineline Cube Jun 3, 2024

The National Healthcare Security Administration (NHSA) has issued the “Procedures for Identification of Drug and...

Company Drug

Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024

Fineline Cube Jun 3, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...

Company Medical Device

Andon Health’s COVID-19 Trio Test Kit and OTC Antigen Test Win FDA Approval

Fineline Cube Jun 3, 2024

Andon Health Co., Ltd (SHE: 002432), a healthcare company based in China, has announced that...

Company

Nanjing Kingfriend Biochemical Gets FDA Nod for Dacarbazine Manufacture at Sagent Facility

Fineline Cube Jun 3, 2024

Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced that...

Company Drug

Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study

Fineline Cube Jun 3, 2024

Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...

Company Drug

Chipscreen’s Chidamide in Sight of Breakthrough Therapy Designation in China for MSS/pMMR Colorectal Cancer

Fineline Cube Jun 3, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...

Company Drug

Simcere Pharma’s Anti-Insomnia Drug Daridorexant Meets Primary Endpoint in Phase III Clinical Trial

Fineline Cube Jun 3, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced topline results from a Phase III...

Company Drug

ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of Timdarpacept in CMML

Fineline Cube Jun 3, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Receives Positive CHMP Opinion for NSCLC Treatment in Europe

Fineline Cube Jun 3, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced that it has...

Company Deals

MSD to Acquire Ophthalmology Specialist Eyebiotech in a Deal Valued Up to USD 3 Billion

Fineline Cube May 31, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into an agreement to acquire UK-based...

Company Drug

FDA Extends Indication for BMS’ CAR-T Therapy Breyanzi to Include Relapsed MCL in Adults

Fineline Cube May 31, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Drug

Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market

Fineline Cube May 31, 2024

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...

Company Drug

Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain

Fineline Cube May 31, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Deals

TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China

Fineline Cube May 31, 2024

Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered...

Company Deals

Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China

Fineline Cube May 31, 2024

Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...

Company Deals

Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development

Fineline Cube May 31, 2024

Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin...

Company Drug

Hengrui Pharmaceuticals Advances Two Drug Candidates Following NMPA Clinical Trial Green Lights

Fineline Cube May 31, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Posts pagination

1 … 390 391 392 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.